FDA Approves QULIPTA for Material Threat Medical Countermeasure Priority Review Voucher

Summary

The FDA has approved QULIPTA (atogepant) tablets, which redeem a material threat medical countermeasure priority review voucher, following the issuance of a notice under the Federal Food, Drug, and Cosmetic Act.